Introduc8on’ Precision,’Stability’and’Reproducibility’...
Transcript of Introduc8on’ Precision,’Stability’and’Reproducibility’...
HIGH DIMENSIONAL FLOW CYTOMETRY FOR COMPREHENSIVE IMMUNE MONITORING IN CLINICAL TRIALS
Dominic Gagnon, Yoav Peretz, Marylène For8n, Claire Landry, and David Favre ImmuneCarta Services, 2901 Rachel Est, Suite 22, Montréal, QC, Canada, H1W 4A4
Introduc8on
Immune Monitoring
Data Analysis
Precision, Stability and Reproducibility
Conclusions
Study Cases of Immune Monitoring
Freq
uency)(%
CD8))
Freq
uency)(%
CD4))
Figure 14: Study protocol and immune monitoring of the AGS-‐004 pilot study to invesNgate the safety and immunologic acNvity of an autologous HIV immunotherapeuNc agent. (NCT00381212) ICS and CFSE prolifera8on assays were performed as indicated in the study protocol (leW). The frequencies of the HIV(GNRV)-‐specific CD8 and CD4 T cell responses and their func8onal profiles (CD107a, IFNγ and IL-‐2) (right) are compared between baseline and visit 8 aWer vaccine administra8on. Pie charts represent the rela8ve distribu8on of the func8onal subsets within the total CD8 and CD4 T cell pools. Sta8s8cal significant differences (P < 0.05) between pre (V2)-‐ and post (V8)-‐vaccine 8me points are indicated by Wilcoxon-‐Rank and a Student’s t-‐test (# and +, respec8vely). The 90th and 75th percen8le threshold applied to background subtracted CD8 and CD4 T cell responses were 0.01% and 0.005%, respec8vely.
Pre-‐treatment Phase
Vaccine ART
Vaccine ARTI
Booster Phase
Follow-‐up & Safety
ART: an8-‐retroviral treatment ARTI: ART interrup8on
V6 V2 V9
90 mL 90 mL 90 mL 90 mL 90 mL 90 mL
Client PRODUCT PRODUCTION
ImmuneCarta DC TARGET PRODUCTION
w0 w4 w8 w12 w16 w20
V8 V3 V13
Vaccine Treatment
Visit/Week
Samples
wk0 wk8 wk16 wk20 wk24
BASELINE IM SAMPLES
POST-‐THERAPY IM SAMPLES
Immune Monitoring
ICS ICS and CFSE
CFSE CFSE CFSE CFSE
Exported as “Experiment” from Diva database to Raw
Data Server
.fcs files read from Raw Data Server on FlowJo template
.jo, .csv, and .PDF from FlowJo saved in
Derived Data Server
Batch layout PDF, and data table saved in Derived Data Server
QA if needed
Assay Acquisi8on Sta8on
Raw Data Server
Analysis Sta8on
Derived Data Server
QC Sta8on Client Report
• Another analyst on another iMac analysis sta8on
• Verify ga8ng and documenta8on
• Confirm data report across all files
• Phenotyping • Func8onal profiling • Enumera8on • ICS • Prolifera8on • PhosFlow • Cyotkine bead arrays
• BD Diva/ LSR II • Daily and monthly QC • Acquisi8on template applied
• Applica8on sepngs used • Compensa8on and staining references
• Delete/modify restricted
• Regular backup
• Presenta8ons • Data Table • PDF
• iMac analysis sta8on • Import FlowJo assay template
• Exploratory analysis can also be done with SPICE/PRISM
• Users can only create or read files
• Regular backup
Figure 9: Flow of work for data analysis. Sample processing, assays and data acquisi8on are based on pre-‐approved worksheets related to study requirements. Samples are acquired on BD LSR II cytometers based on pre-‐defined sepngs and templates. The raw FACS data are exported directly to the Raw Data server and used on FlowJo analysis template on the Derived Data server. Once analysis has been completed and documented, a full QC of data analysis is performed. Final client data and report are generated, while the whole process is audited by the Quality Assurance (GLP studies).
Figure 2: Overview of immune monitoring services. ImmuneCarta Services include all steps from strategic planning to final reports to clients. It oWen involves study set-‐up, lab manual wri8ng and sample management which are cri8cal steps for cell-‐based analysis as flow cytometry assays. Customized assays as per client needs require assay development and valida8on prior to immune monitoring of clinical samples. All steps include an ac8ve follow-‐up with the sponsor, are performed using proprietary SOPs and worksheets and are documented as per applicable GLP regula8ons.
Strategic Planning and Communica8on
Pro-‐ac8ve Rela8onship with Sponsors, CRO, and Clinical Sites
Standard and Customized Immune Monitoring Assays
Study Progress and Final Report to Sponsor
• Innova8on and development program • Design of immune monitoring strategy and workplan • Ph.D.-‐level Principal Scien8sts assigned to each study
• Involved in study set-‐up, lab manual wri8ng, and sample management • On-‐site training of clinical sites for maximum sample viability and recovery
• Assay development, qualifica8on, and valida8on; SOP & worksheets • Data integrity, high quality and high throughput processing and analysis • Documenta8on, sample tracking and control, GLP/GCLP training
• Conference calls, interim and final scien8fic reports • Quality Assurance Statement • Ac8ve par8cipa8on in scien8fic posters and publica8ons
Figure 8: Reproducibility and %CV from external QC samples: results obtained with BD MulN-‐check CD4 low controls in 14 experiments with lot # 40L in April 2010 and 17 experiments with lot # 50L in May 2010. The first graph represents the enumera8on of lymphocytes (CD45), T cell popula8ons (CD3, CD4, and CD8), B cells, and NK cells. The second graph represents the enumera8on of the same popula8ons. Coefficient of varia8on are indicated in blue.
CD4 Low control, lot # 40L
CD45 CD3CD4
CD8 B NK0
250
500
750
1000
1250
1500
Populations
Count/uL
CD4 Low control, lot # 50L
Populations
Count/uL
CD45 CD3CD4
CD8 B NK0
250
500
750
1000
1250
1500
2.5 3.1 3.7 4.1 3.1 3.2 5.0 4.9 5.6 4.7 5.6 5.2
Beads
0 102 103 104 105
FITC-A
0
20
40
60
80
100
% o
f Max
Ungated
0 50K 100K 150K 200K 250KFSC-A
0
20
40
60
80
100
% o
f Max
Beads
0 102 103 104 105
PE-A
0
20
40
60
80
100
% o
f Max
Beads
0 102 103 104 105
PerCP-A
0
20
40
60
80
100
% o
f Max
Beads
0 102 103 104 105
FITC-A
0
20
40
60
80
100
% o
f Max
Beads
0 102 103 104 105
PE-A
0
20
40
60
80
100
% o
f Max
Beads
0 102 103 104 105
PerCP-A
0
20
40
60
80
100
% o
f Max
Ungated
0 50K 100K 150K 200K 250KSSC-A
0
20
40
60
80
100
% o
f Max
Figure 4: Stability of the signal using applicaNon seangs coupled with CS&T. Compbeads were stained 45 8mes with either FITC, PE or PerCP (3 month survey) and were used to determine compensa8on for 81 experiments using cytometer # 1 and 31 experiments using cytometer # 2. Voltages were determined by the Applica8on Sepngs linked to the daily CS&T Performance check. First row: 11-‐color cytometer, second row, 18-‐color cytometer with yellow-‐green laser (see increased posi8ve PE signal without increasing the background).
FITC PE PerCP FSC/SSC
LSR II # 1
LSR II # 2
Serum aliquoNng/storage
ELISA assays: -‐ Vaccine Nters -‐ Soluble markers
Other soluble markers
ImmuKnow Assay
Performed at ImmuneCarta Services
Performed at collaborator sites
Flow cytometry T cell panel (12 colors) Innate panel (12 colors)
Cell pellet cryopreservaNon
DNA analysis (SNP/telomeres)
Paxgene tube storage
RNA/mRNA analysis
Ficoll
PhosFlow
Flow cytometry B cell panel (11 colors)
PBMC cryopreservaNon
Figure 3: Example of sample management for assays performed at ImmuneCarta Services and at collaborator sites. In this vaccine clinical trial on 200 subjects, ImmuneCarta provided mul8ple services including study design, central lab ac8vi8es, assays and integrated analy8cal report. In this example, fresh blood samples from each subject and each 8me point were collected at a CRO site nearby and immediately processed for analysis at ImmuneCarta or stored at ImmuneCarta for analysis at collaborator sites, e.g. genomics, gene8c, other soluble markers or PhosFlow.
Figure 5: Reproducibility of CD34+ absolute counts using reference QCs over Nme. Three levels of CD-‐Chex CD34 reference controls were used (3, 35, and 124 CD34 cells/µL) and two BD Stem Cell Control Kit (12.1 and 35.9 CD34 cells/µL). Coefficient of varia8on for CD-‐Chex level 1, 2, and 3 are respec8vely 8.98%, 3.84%, and 1.98%. For BD Stem cell low and high reference controls, the CV are respec8vely 6.94% and 3.48%.
25-F
eb-20
11
28-F
eb-20
11
1-Mar-
2011
2-Mar-
2011
4-Mar-
2011
8-Mar-
2011
11-M
ar-20
11
28-M
ar-20
11
29-M
ar-20
11
31-M
ar-20
11
1-Apr-
2011
6-Apr-
2011
8-Apr-
2011
0
5
10
15
20
25
30
35
40
45
50
12.1
BD Stem Cell Control LOWBD Stem Cell Control HIGH
Target value
+ 20%
- 20%
Target value+ 20%
- 20%
CD
34 c
ount
(cel
ls/µ
L)
25-F
eb-20
11
28-F
eb-20
11
1-Mar-
2011
2-Mar-
2011
4-Mar-
2011
8-Mar-
2011
11-M
ar-20
11
28-M
ar-20
11
29-M
ar-20
11
31-M
ar-20
11
1-Apr-
2011
6-Apr-
2011
8-Apr-
2011
0
2
4
6
3
50
100
150
283542
124
CD-CHEX CD34+ Level 3CD-CHEX CD34+ Level 2CD-CHEX CD34+ Level 1
Target value
+ 20%
- 20%
Target value+ 30%
- 30%
Target value+ 20%
- 20%
CD
34 c
ount
(cel
ls/µ
L)
Discovery Pre-‐clinical Phase I Phase II Phase III Phase IV /
Market
Figure 13: SchemaNc of the drug discovery process.
Table I: Overview of ImmuneCarta assays in different fields of applicaNon and therapeuNc areas.
ImmuneCarta Services is a leading provider of services for preclinical and clinical studies related to immunology. Over the past 7 years, we have developed a broad bayery of innova8ve assays to characterize cell popula8ons and immune responses in the sepng of infec8ous diseases, cancer, vaccine trials and immune-‐based therapies. Based in Montréal, ImmuneCarta Services is specialized in advanced mul8parametric flow-‐based assays performed according to GLP regula8ons, GCLP guidelines governed by Quality Management Systems and standard opera8ng procedures. ImmuneCarta exper8se includes the assessment of phenotypic and func8onal markers, the characteriza8on of cell subset lineages, ac8va8on states, and signaling molecules, as well as the quan8ta8ve analysis of vaccine-‐, pathogen-‐ or drug-‐specific responses based on an8body signatures, cytokine/chemokine profiles, and signaling pathways. We describe here our experience as a contract research organiza8on providing services to the biopharmaceu8cal industry, in the execu8on of high dimensional flow cytometry analysis of subjects enrolled in Phase I/II clinical trials.
Flow cytometry is a unique way to address complex cellular immunological profiling for drug development and Phase I-‐III clinical trials in infec8ous diseases, cancer, vaccine, transplanta8on, autoimmune disorders and related immunomodula8on-‐based therapies. High dimensional mul8parametric single-‐cell analysis is not only aimed to define mul8ple markers of different cell popula8ons simultaneously -‐though helpful when clinical sample availability is limited-‐, it is also one of very few analy8cal plazorms that can address complex protein-‐based signatures (biomarkers, disease stage, etc.) and func8onal networks (mechanisms) from relevant and well-‐characterized primary human or animal cells at the single cell level. The immune monitoring of Phase I to Phase III clinical trials aims to design, perform and interpret immunological data that enable industry to move vaccines, immunotherapeu8cs and drug candidates through the regulatory process (FDA, EMEA, others). High dimensionality flow cytometric analysis also allows for the defini8on of immunological profiles that are disease and stage specific, enabling elimina8on of many unsuitable drug, vaccine or therapy candidates prior or at the 8me of “in-‐man” studies. This requires both a scien8fic exper8se in immunology, physiology and pathology as well as a clear understanding of technicali8es related to instruments, reagents and high dimensional data mining. As a service company for the pharmaceu8cal industry, ImmuneCarta regulatory process and standardized procedures are cri8cal to ensure data integrity and quality, especially when interpre8ng complex data sets to define disease stage, drug efficacy or toxicity. Overall, immune assays for diagnos8c, research or biomarker discovery may impact on all aspects and stages of immune system tes8ng, vaccine and immunotherapeu8c design and development as well as drug screening. They are enablers, permipng GO/NO-‐GO decision-‐making, thus saving both 8me and money, enhancing safety and providing surrogate markers of clinical efficacy and/or mechanis8c insights.
Flow cytometry is based on fluorescence, fluidic and op8cal tools with the help of signal and image computer treatment. ImmuneCarta Services uses 3-‐ and 4-‐laser LSR II Becton Dickinson instruments. These instruments are high performance systems allowing simultaneous analysis of up to 18 colors using automated sampler in 96-‐well plate format. High dimensional flow cytometry requires sensi8ve and precise methods with op8mal stability and reproducibility of the signal. For customized an8body panels, qualifica8on or valida8on steps are necessary to address specificity, precision, accuracy, lower and upper limits and range of detec8on, stability and reproducibility of the analysis. The precision and accuracy of flow cytometry experiments also depends on stable applica8on sepngs (CS&T beads) as well as internal and/or external quality control (QC) samples.
Since 2004, ImmuneCarta has applied a broad array of innova8ve assays for the biopharmaceu8cal industry and government ins8tu8ons to characterize the immune profiling of adap8ve and innate immunity and the potency of immune-‐related drugs or vaccines in exploratory and Phase I and Phase II clinical trials. ImmuneCarta Services recently formed a strategic alliance with Caprion Proteome Inc., the leading company in proteomics and biomarker discovery (www.caprion.com) in order to integrate single-‐cell mul8parametric flow cytometry analysis with soluble markers, serological measurements and other large datasets including genomics and proteomics.
High throughput analysis of high dimensional flow cytometry data requires advanced soWware and methods. Data analysis performed at ImmuneCarta Services relies on flow data acquisi8on using DiVa soWware (BD Biosciences), and data analysis with FlowJo (Treestar Inc.), Excel (Windows), PESTLE/SPICE (NIH), Cluster (Open source, Stanford), Java TreeView (Open source), Prism (GraphPad SoWware) and/or other specialized soWware for sta8s8cal analysis and systems biology. All data are acquired and analyzed in compliance with 21 CFR Part11 to ensure quality and integrity of the raw data and its analysis. Pre-‐defined FlowJo templates are qualified or validated (GLP study) prior to being used throughout studies and require minimal ga8ng adjustments that are documented accordingly.
Over the past 7 years, we have implemented assays using high throughput analy8cal methods with 10 to 18-‐flow cytometry parameters on fresh and cryopreserved human peripheral blood samples. Overall, immune monitoring of clinical trials involve study planning, assay valida8on, specimen handling, assay execu8on, monitoring, repor8ng, and quality review performed as per applicable GLP regula8ons and GCLP guidelines governed by quality systems and standard opera8ng procedures.
0 10 20 30 40 50 600
10
20
30
40
50
60
V2
V2-
redo
Switched IgGSwitched IgAUnswitched IgMMZ-likeImmature B cellNaive IgM-IgD+Naive IgM+IgD+Naive IgM+IgD-Memory IgA+Memory IgG+Memory IgM+IgD+Memory IgM+IgD-Memory IgM-IgD+Plasma B cellsPlasma IgA+Plasma IgD+Plasma IgG+Plasma IgM+
% Parent
Figure 6: Reproducibility of high dimensional flow cytometry. Phenotyping of T, B, and innate cells using 11-‐12 color an8body panels was assessed independently on two blood samples from 20 subjects at Visit 2 (V2 and V2-‐redo). Distribu8on of popula8ons and cell counts are highly correlated with R2 > 0.99.
Innate cell Counts
0 20 40 60 80 1000
20
40
60
80
100CD28- (CD8)CD4 (CD3)CD8 (CD3)PD-1 (CD4)PD-1 (CD8)CD57 (CD4)CD57 (CD8)Naive (CD8)CM (CD8)EM (CD8)TEM1 (CD8)TEM2 (CD8)
ILD (CD8)LD (CD8)Naive (CD4)CM (CD4)EM (CD4)TEM1 (CD4)TEM2 (CD4)ILD (CD4)LD (CD4)Mem CD45RA- (CD8)Mem CD45RA- (CD4)
V2
V2-
Red
o
% Parent
T cell Subsets B cell Subsets
0 400 800 1200 1600 20000
400
800
1200
1600
2000
V2
V2-R
edo
CD3 CD4CD8DPDNB cells HLA-DR+ B cells HLA-DR- MonocytespDCmDC1mDC2All NKNK 56-16+ NK 56bright16-NK 56low16-NK 56low16+NK 56bright16low
Cell counts (cells/µL)
R2 = 0.9956 R2 = 0.9955 R2 = 0.9954
Figure 7: Reproducibility and %CV from internal QC samples (frozen PBMC, L747) on 11-‐color T, B, and Innate cell phenotype panels. Results from 32 experiments are shown over one year (July 2010 to September 2011). The first graph represents the enumera8on of T cell popula8ons (CD3, CD4, and CD8). The second graph represents the enumera8on of B cells, the monocytes, and sub-‐popula8ons of dendri8c cells. The third graph represents the enumera8on of natural killer (NK) sub-‐popula8ons. Coefficient of varia8on are indicated in blue.
B, mono, and DC L747
B ce
lls HLA
-DR+
B ce
lls H
LA-D
R- Mon
oPDC
mDC1mDC2
0
10
20
30
40
50
500
1000
1500
B, Mono, and DC Populations
Co
un
t / u
L
T Cells L747
CD3
CD4
CD8 DP DN0
100
200
300
2000
4000
6000
8000
10000
T Cells Populations
Co
un
t / u
L
NK L747
ALL N
K
NK 56-1
6+
NK 56br
ight16
-
NK 56low
16-
NK 56low
16+
NK 56br
ight16
low0
50
100
150
200300
400
500
600
700
800
NK Populations
Co
un
t / u
L
18 18 19 39 38 36 66 44 29 24 31 18 36 23 38 19 23
Subj-‐1
Subj-‐1
Subj-‐2
Flow Cytometry Single-‐cell analysis (% funcNonal response) StaNsNcal analysis and idenNficaNon of group differences in funcNonal responses
Sample
Figure 1: Overview of ImmuneCarta flow cytometry and analyNcal processes (example of immune profiling of mucosal CD4+ T cells by intracellular cytokine detecNon)
Plamorm Field of applicaNon Main therapeuNc area
Assays Targeted Sample or Cell PopulaNon Markers
Custom
izab
le
Flow
Cytom
etry
Cytokine
bead array
ELISA/ELISPO
T
Chem
iluminescence
Molecular biology
Drug develop
men
t
Biom
arkers
Biologics/Biosim
ilars
Immun
e Mon
itorin
g
Vaccine
Epito
pe M
apping
Immun
otoxicology
Infec8ou
s dise
ases
Allergy
Oncology
Cardiology
Autoim
mun
ity
Transplanta8
on
Immun
e Sene
scen
ce
Chronic Inflamma8
on
Cell EnumeraNon
HematopoieNc stem cells Circula8ng CD34+ CD34, CD45, others ✓ • • • • • • Immune Cells T, B and Innate cells CD3, CD4, CD8, CD16/56, CD19, CD14, CD11c, CD45, CD123, others ✓ • • • • • • • • • • • • • • Tumor Cells Circula8ng Tumor Cells DNA, Cytokera8n, CD45 • • • •
Immune Phenotyping
Cell Lineage T, B, NK and NKT cells, Dendri8c cells, Basophils, Monocytes CD3, CD4, CD8/CD19, HLA-‐DR/CD16, CD56, Lin-‐/Vα24, αGalCerCD1d tetramer, CD3/CD11c, CD123, Lin-‐/CD123, Lin-‐/CD14 ✓ • • • • • • • • • • • • • • •
Cell Subsets DifferenNaNon T, B, NK and NKT cells, Dendri8c cells, Basophils, Monocytes CD45RA/RO, CD27, CCR7, CD28, CD62L/CD27, IgD/M, CD20,
CD38,CD10,IgA/G/E/CD94/NKG2A, CD7, KIR2DL/DS/CD11c,/CD123, BDCA-‐2/3/4, /FcγRs, IgE, CCR3/CD16, CD64, FcγRs
✓ • • • • • • • • • • • • • • •
AnNgenic specificity Tetramer-‐posi8ve an8gen-‐specific CD8+/CD4+ T cells An8gen-‐specific, HLA-‐restricted TCR (using Tetramer/Pentamer/Dexamer) ✓ • • • • • • • • • • AcNvaNon/InhibiNon/ExhausNon/ Immune
Senescence T, B and Innate cells HLA-‐DR, CD38, ICOS, OX40, 4-‐1BB, Ki67, CD40, CD95, PD-‐1, CD57, CD83, CD80, CD86, CD160, Lag-‐3, 2B4, CTLA-‐4, Tim-‐3 ✓ • • • • • • • • • • • • • • •
Homing Receptors/Co-‐receptors T cells, B and Innate cells CCR4, CCR5, CCR6, CCR7, CCR9, CXCR3, α4β7 integrins, others ✓ • • • • • • • • • • • • • TranscripNonal Factors Treg, Th1, Th2, Th17, T~ FoxP3, T-‐bet, GATA-‐3, RORγt, BCL-‐6 ✓ • • • • • • • • • • • •
FuncNonal Profiling
Intracellular Cytokine/Chemokine Staining T, B, NK, NKT, Dendri8c cells, Monocytes IL-‐2, TNFα, IFNγ, IL-‐4, IL-‐17, IL-‐22, IL-‐10, TGFβ, IL-‐9, IL-‐21, Mip1β, others ✓ • • • • • • • • • • • • • • • • Apoptosis/Necrosis T, B and Innate cells Annexin, caspase 3, CD95, PARP, TUNEL, Live/Dead, 7-‐AAD ✓ • • • • • • • • • • • • • • •
PhosphorylaNon (PhosFlow) T, B and Innate Cells, Tumor cells Akt, Btk, Elk, EGF-‐R, Lck, LAT, Zap70, Syk, MEK1, NFκB, PKC, PLC-‐γ1, PLC-‐γ2, p38MAPK, ERKk1/2 Src, STAT1 to STAT-‐6 ✓ • • • • • • • • • • • • • • • •
Lymphocyte acNvity (ImmuKnow®) Total CD4 cells ATP • • • • • • • • • • ProliferaNve response/cell cycling T cells and subsets CFSE, Ki67, BrDU ✓ • • • • • • • • • • • • • • • •
ELISPOT CD8+/CD4+ T cells, B cells IFNγ and/or IL-‐2, TNFα, IgG, IgM ✓ • • • • • • • • • Cytotoxicity/DegranulaNon T, NK, NKT cells and subsets, Basophils CD107a, Granzyme, Perforin, CD63, others ✓ • • • • • • • • • • • • • • •
Serology & Soluble Markers
AnNbody Titers Serum, plasma Tetanus, Diphtheria, Hepa88s B, Cholera toxin B, CMV, others • • • • • • • • • • • • Cytokines/Chemokines/Adhesion
Molecules/Growth Factors Serum, plasma, cell culture supernatant Interleukins, sICAM-‐1, sICAM-‐3, sVCAM-‐1, sPECAM-‐1, sE-‐Selec8n, sP-‐ Selec8n, G-‐CSF, IL-‐8, MCP-‐1, MIG, MIP-‐1α, MIP-‐1β, others ✓ • • • • • • • • • • • • • • • • •
Gene Expression & DNA Analysis
mRNA expression (real-‐Nme PCR) Cells, 8ssue Specific mRNA quan8fica8on ✓ • • • • • • • • • • • • • T cell receptor excision circles (TREC) Cells, 8ssue sjTREC • • • • • • • •
Final data and report exported in Study Server
Figure 12: Boolean gaNng analysis of 5 markers in mucosal CD4+ T cells using SPICE analysis. CorrelaNon of specific funcNonal signatures with immune acNvaNon (Ki67+). Combina8on of 3 among 5 markers (IFNγ, IL-‐2, IL-‐17, MIP1β, and TNFα) are displayed as dots and their means, as grey histograms. Sta8s8cally significant differences between HIV viral controllers and non-‐controllers are shown by # (Wilcoxon-‐Rank) and + (Student’s t-‐test).
Figure 10: Example of a simple hierarchical gaNng for T, B and NK cell enumeraNon. Lymphocytes and BD TruCount Beads are gated based on SSC/CD45 expression. CD3-‐posi8ve and CD3-‐nega8ve popula8ons are defined. From CD3-‐ gate, natural killer (NK) and B cells are discriminated based on CD16/CD56+ (NK) and CD19+ (B cells). From CD3+ gate, CD4+ and CD8+ T cells are defined as well as double nega8ve and double posi8ve T cells.
<FITC-A>: CD3
70.829.2
<APC-Cy7-A>: CD8
<PE
-Cy7
-A>:
CD
4
<APC-A>: CD19
SSC
-A
<APC-A>: CD19
<PE
-A>:
CD
16/C
D56
<PerCP-Cy5-5-A>: CD45
SS
C-A
Beads
Lymph CD3+
NK
B Cells
CD4 DP
CD8DNCD3-
Figure 11: Example of Boolean gaNng of 6 funcNonal markers expressed in CD4+, CD8+ or memory subsets and effector T cells by ICS aoer anNgen-‐sNmulaNon of cryopreserved PBMCs. Posi8ve responses for each of the markers are defined from the template analysis (IFNγ, CD107a, TNFα, IL-‐2, IL-‐4, and IL-‐17). Boolean ga8ng is generated by FlowJo for all possible combina8ons (IFNγ+/-‐ and CD107a +/-‐ and TNFα+/-‐, and IL-‐2+/-‐ and IL-‐4+/-‐ and IL-‐17+/-‐ ), e.g. leading to 2n different gates. In this example, n = 6, genera8ng 64 gates for 8 popula8ons of interest per sample.
Boolean Gating (total CD4+ and CD8+ T cells):
CD107a TNFa IL-2IFNg IL-17IL-4
CD
8+ T
cel
lsC
D4+
T c
ells
0.130.354
0.157 0.05540.0294
1.68e-3
0.6720.734
0.623 0.06140.0154
3.07e-3
Titer DistribuNons of Vaccinated Subjects Cytometric Vaccine Response Examples
Plasmacyte Counts before (V2) and after (V3) immunization (left) All Plasmacytes (right) IgG+ Plasmacytes
High Dimensionality Analysis of Hyporesponsiveness to Protein Subunit Vaccines in the Elderly -- Introduction to Study MK0000-131
Carayannopoulos LN1,, Railkar RA1, Favre D2, Landry C2, Schaeffer AK1, Wiener MC1, Chastain M1, Loboda A1, Lukac S1, Duguay D3, Audet D3, St-Maurice F3, Kaslow DC1, Beals CR1, Sekaly RP2,4
1Merck Research Laboratories, USA | 2National Immune Monitoring Laboratory – Genome Quebec, Canada | 3Anapharm-Pharmanet Quebec, Canada | 4VGTI-Florida
6
wk24 wk28
Figure 15: High dimensionality analysis of vaccine hyporesponse in healthy elderly subjects (NCT01119703) Titer distribu8on of vaccine responses to Tetanus, Diphtheria and Hepa88s B vaccines in elderly subjects (leW) and example of increase frequency of highly characterized B cell popula8ons one week (V3) aWer vaccine administra8on (V2) (middle). “Plasma B cells” are characterized as singlet/lymphocyte/CD19+/HLA-‐DR+/CD3-‐/CD27+/CD10-‐/CD20-‐ cells. “Plasma IgG+ B cells” are plasma B cells expressing IgG on the cell surface. An example of heatmap represen8ng unsupervised clustering of high dimensional flow cytometric Boolean datasets of T, B and innate immune phenotyping (y-‐axis) is shown on the same cohort (N=120 subjects, x-‐axis) (right). Such unsupervised clustering of large flow cytometric datasets allows further analysis of genomic datasets or other large datasets by quan8ta8ve regression analysis related to individual immune profiling, as described in Loke, Favre et al., Blood 2010.